BioAgilytix leverages the Meso Scale Discovery Electrochemiluminescence (MSD-ECL) platform and its plate-based electrochemical luminescence technology to provide reliable, high quality data for a diverse variety of biological assay needs, particularly those characterized by high sensitivity and high tolerance to circulating antigen.
Learn More About the MSD Platform:
BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.
The MSD-ECL platform uses electrochemiluminescent labels that are conjugated to detection antibodies. These labels generate light when stimulated by electricity in the appropriate chemical environment, which can then be used to measure key proteins and molecules.
The detection process is initiated at electrodes located in the bottom of the platform’s microplates, and only labels near the electrode are excited and detected. Electricity is applied to the plate electrodes, leading to light emission by SULFO-TAG labels, which are electrochemiluminescent labels that allow for ultra-sensitive detection. Light intensity is then measured to quantify analytes in the sample. The MSD-ECL platform employs buffers with high concentrations of Tripropylamine as a catalyst for a dual redux reaction with Rethenium, emitting light at 6:20 nm.
The MSD-ECL platform offers great flexibility with stable, non-radioactive, and easily conjugated labels. Because of these factors, it makes a strong alternative to conventional colorimetric methods like ELISA when higher sensitivity and multiplexing are critical. We have also found MSD assays are optimal for complex matrices as they typically yield low interference from components like serum or plasma. MSD is particularly advantageous in that its bridging formats are not specific for species or antibody subclass.
BioAgilytix’s scientists most frequently utilize Meso Scale Discovery (MSD-ECL) in our work with biomarkers, immunogenicity, pharmacokinetics (PK), cell-based assays, and lot release testing. We are able to run MSD assays in support of non-GLP, GLP, and product release testing under GMP using samples from rodents, humans, and non-human primates.
BioAgilytix’s scientists are proven experts at multiplexing on the Meso Scale Discovery platform (MSD-ECL), and our lab has been selected as the first to validate MSD’s Human Cytokine 30-Plex V-PLEX Kit.
We have particular expertise using MSD-ECL for complex matrices, and have had proven success meeting the demands of even the most challenging bioanalytical assays.
Learn how we can support your unique assay requirements with the MSD platform today.